RNA Biomarker Detection for HDAC6 Inhibitor Dose Quantification

Solution Overview

Problem

Current HDAC6 inhibitors lack a reliable method for determining a pharmacologically active dose due to the absence of toxic side effects, making it challenging to define a dose in clinical development, and existing methods for assessing antitumor activity are qualitative or semi-quantitative.

Innovation Solution

A method involving the determination of specific gene expression signatures, particularly the modulation of RNA biomarkers such as CD84, RANK/TNFRSF11a, CXCL3, CXCL2, STAB1, CD163, CD204/MSR1, CD206/MRC1, MMP9, NBEAL2, LTBP4, ANXA6, FATP1/SLC27A1, ADA, CD40, and IRF6, to evaluate the efficacious dose and biological activity of HDAC6 inhibitors like N-hydroxy-4-((5-(thiophen-2-yl)-1 H-tetrazol-1-yl)methyl) benzamide (ITF3756) in cancer treatment.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Object-affected harmful factors

If selective HDAC6 inhibitors are used to treat cancer, then therapeutic potential is improved with better pharmacological capabilities and reduced toxicities, but the ability to determine efficacious dose is worsened due to lack of toxic side effects

Engineering Contradiction:
Core Design Contradiction:
Object-affected harmful factorsVSMeasurement precision

Solution Approach 1:

The patent introduces RNA biomarkers as intermediary molecules that mediate between HDAC6 inhibitor treatment and measurable cellular responses. These biomarkers serve as surrogate indicators that allow dose determination without relying on toxic side effects, thus resolving the contradiction between reduced toxicity and dose determination capability

Inventive Principle:
Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent replaces the traditional mechanical/toxicity-based dose determination system with a molecular biology-based system using RNA biomarker expression analysis. This substitution enables precise dose measurement through molecular signatures rather than through toxicological endpoints

Inventive Principle:
Principle #28Mechanics substitution (Replace mechanical system)

2Ease of operation

If existing methods are used to assess antitumor activity, then simplicity is maintained, but measurement precision is worsened due to qualitative or semi-quantitative nature

Engineering Contradiction:
Core Design Contradiction:
Ease of operationVSMeasurement precision

Solution Approach 1:

The patent replaces qualitative/semi-quantitative assessment methods with quantitative real-time PCR technology. This substitution maintains operational simplicity while dramatically improving measurement precision by providing numerical quantification of RNA biomarker expression levels that correlate with antitumor activity

Inventive Principle:
Principle #28Mechanics substitution (Replace mechanical system)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach allows for the classification of patients as responsive or non-responsive to HDAC6 inhibitor treatment based on gene expression levels, providing a quantitative method to assess the biological activity and efficacious dose, correlating with antitumor effects in cancer therapy.

Implementation Method 1

A method involving the determination of specific gene expression signatures, particularly the modulation of RNA biomarkers

Methodology Applied
Scientific EffectNucleic acid hybridization:

Data Source

PatentUS20250011878A1Method to detect RNA biomarkers
Publication Date: 2025.01.09
  • US20250011878A1 patent drawing
  • US20250011878A1 patent drawing
  • US20250011878A1 patent drawing

AI summary

The present invention relates a method based on mRNA biomarkers that can be used to define the efficacious dose and/or the biological activity of inhibitors of histone deacetylase 6 (HDAC6), such as the compound N-hydroxy-4-((5-(thiophen-2-yl)-1H-tetrazol-1-yl)methyl) benzamide, during the clinical treatment of patients affected by cancer. More in particular, the invention refers to the analysis of the gene expression's variation of specific biomarkers in human monocytes, as “gene expression signatures”, in a method to evaluate the clinical efficacy of HDAC6 inhibitors, such as the compound N-hydroxy-4-((5-(thiophen-2-yl)-1H-tetrazol-1-yl)methyl)benzamide.